G1 enters lung cancer trial collaboration with AstraZeneca
G1 Therapeutics Inc. will study its investigational CDK inhibitor G1T38 in combination with AstraZeneca PLC’s EGFR inhibitor Tagrisso (osimertinib) under a recently signed clinical trial collaboration.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com